Conference Coverage Archives - Page 70 of 70 - Cancer Therapy Advisor

Conference Coverage

No Improvement When Bevacizumab Added to Trastuzumab and Chemo in Metastatic Breast Cancer

Adding bevacizumab to first-line chemotherapy and trastuzumab was safe and well tolerated in patients with HER2+ metastatic breast cancer; however, no significant differences in clinical benefit or measurements in circulating tumor cells (CTCs) were observed, according to results of a phase 3 clinical trial presented at the 2012 American Society of Clinical Oncology Annual Meeting.

No Survival Gains Seen with Nimotuzumab in Glioblastoma but More Study Warranted in Patients with MGMT Nonmethylated Glioblastoma

Nimotuzumab does not improve survival among newly diagnosed glioblastoma patients when added to standard temozolomide chemoradiotherapy, but warrants further study among patients with MGMT nonmethylated glioblastoma, according to a randomized multicenter phase 3 study reported at the 2012 American Society of Clinical Oncology Annual Meeting.

In Relapsed Ovarian Cancer, Topotecan + Carboplatin Failed to Improve PFS, OS

Topotecan plus carboplatin failed to improve progression-free survival (PFS) or overall survival (OS) compared with standard therapy (paclitaxel/carboplatin, gemcitabine/carboplatin, or carboplatin/pegylated doxorubicin) in patients with platinum-sensitive relapsed ovarian cancer, according to results of the randomized phase 3 HECTOR study presented at the 2012 American Society of Clinical Oncology Annual Meeting.

Next post in ASCO 2012